Euronav (NYSE:EURN) Lifted to Buy at Stifel Nicolaus

Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its price objective reduced by BMO Capital Markets from $20.00 to $19.00 in a research report report published on Tuesday, The Fly reports. A number of other research firms have also recently weighed in on FHTX. Bank of America began coverage on shares of Foghorn Therapeutics in a […]

Related Keywords

United States ,America , ,America Corp ,Barclays Plc ,Foghorn Therapeutics Company Profile ,Wells Fargo Company ,Foghorn Therapeutics Inc ,Nasdaq ,Tower Research Capital ,Foghorn Therapeutics ,Get Rating ,Moderate Buy ,Therapeutics Trading Down ,Research Capital ,Therapeutics Inc ,Gene Traffic Control ,Foghorn Therapeutics Daily ,Nasdaq Fhtx ,Fhtx ,Medical ,Lower Price Target ,Bmo Capital Markets ,